AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

India's drug regulator has allowed AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine to be used for up to nine months from its manufacture date, versus the prescribed six months, according to a document reviewed by Reuters and a source. The approval is expected to minimize vaccine wastage and better plan the inoculation programs.

India Extends Shelf Life For AstraZeneca COVID-19 Jab To Nine Months: Reuters

Canada has temporarily stopped giving AstraZeneca's COVID-19 vaccine to people under 55 while it investigates cases of an unusual blood-clotting disorder in Europe. Canadian officials said there were reports from Europe of a clotting disorder among some vaccinated people in Europe, particularly among young women, called Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT). In this disorder, antibodies "activate" platelets and cause blood clots to form.

Canada suspends the AstraZeneca vaccine in under-55s while officials investigate reports of rare blood clots

Germany's vaccine regulator said nine people have died from a rare blood clot in the brain after taking the AstraZeneca coronavirus vaccine, Reuters reported, citing a statement from the Paul Ehrlich Institute. Seven of the deaths were in women between 20 and 63 years old.

German regulator reportedly says nine have died from blood clots after taking AstraZeneca vaccine

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.

Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?

The National Advisory Committee on Immunization recommendation came just days after the Canadian health department had backed the vaccine.

Canadian Panel Recommends Pausing AstraZeneca Vaccine For 55 And Younger

Colgate-Palmolive

Costco

Dollar General

Equinor

Target

Unilever

Safe stocks that have a low beta and hence low volatility. In addition, stocks that have a healthy dividend yield.

7 Safe Stocks to Buy If You're Allergic to Volatility

Los Angeles, California--(Newsfile Corp. - March 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - March 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or...

AZN Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline in Securities Class Action - AZN

AstraZeneca stock was subject to wild swings in 2020 as the company pushed forward in developing a coronavirus vaccine. Now that the firm has authorization in the U.K., is AZN stock a buy?

Is AstraZeneca Stock A Buy As Shares Yo-Yo On Covid Vaccine Woes?

Could AstraZeneca Double Your Money Despite Vaccine Woes?

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 26, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) and reminds investors of the March 29, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in AstraZeneca stock or options...

AstraZeneca Shareholder Alert

New York, New York--(Newsfile Corp. - March 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Astrazeneca Plc (NASDAQ: AZN) alleging that the Company violated federal securities laws.Class Period: May 21, 2020 and November 20, 2020Lead Plaintiff Deadline: March 29, 2021Learn more about your recoverable losses in AZN:

AZN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 29, 2021 in the Class Action Filed on Behalf of Astrazeneca Plc Limited Shareholders

Los Angeles, California--(Newsfile Corp. - March 26, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the...

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - March 26, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Astrazeneca Plc ("Astrazeneca") (NYSE: AZN) between May 21, 2020 and November 20, 2020.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=14159&wire=5

AZN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Astrazeneca Plc

The European Union has stepped up tough rules on the exports of Covid vaccines, while also piling pressure on AstraZeneca to deliver more shots to the region.

EU steps up vaccine exports rules and pressures AstraZeneca over deliveries

AstraZeneca PLC (LON:AZN) was urged to catch up with COVID-19 vaccine deliveries by the EU. "The company.

AstraZeneca urged to catch up with COVID-19 vaccine deliveries by EU chief

AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.

AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine

New York, New York--(Newsfile Corp. - March 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Astrazeneca Plc ("Astrazeneca") (NASDAQ: AZN) between May 21, 2020 and November 20, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Astrazeneca Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 29, 2021 - AZN

Nasal spray vaccines are easier to administer, avoid needles and can even provide better protection against infection.

Nasal Spray Of Covid Vaccine May Be Next: Oxford Reportedly To Test AstraZeneca Version

India has blocked all major exports of the AstraZeneca vaccine to boost domestic supply, the latest move by a country to stop doses from leaving its borders. This could disrupt the rollout of vaccines to poorer countries via the COVAX scheme, which had been counting on Indian-made doses.

India is blocking exports of AstraZeneca vaccines to use for itself, disrupting vaccine rollouts in other countries

AstraZeneca stock rose Thursday after the company said its coronavirus vaccine was 76% effective in a primary analysis of its U.S. final-phase test. It plans to soon ask for authorization.

AstraZeneca's Covid-19 Vaccine Saga Continues With A New Analysis

Los Angeles, California--(Newsfile Corp. - March 25, 2021) - Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class...

MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The shares of AstraZeneca plc (NASDAQ:AZN) have seen a lot of movement lately, with the drugmaker's Covid-19 vaccine popping up in the news  almost daily.

AstraZeneca Revises Vaccine Efficacy Rate, Stock Inches Higher

Denmark's health authority has extended its hold on using the AstraZeneca vaccine for another three weeks. "At this time, we believe that our basis for making a final decision on any future use of the COVID-19 vaccine from AstraZeneca is too uncertain.

Denmark extends suspension for using AstraZeneca vaccine for three weeks

AstraZeneca's Covid shot has always been accompanied by high hopes, but it has been mired in controversy ever since its inception.

News for AstraZeneca Stock (AZN)